Shots:
- The US FDA has accepted 351(k) BLA of AVT03, a biosimilar version of Prolia & Xgeva (denosumab), for all indications of reference product
- As per the 2024 license & supply agreement, Alvotech is responsible for the development & manufacturing of AVT03, while Dr. Reddy’s handles registration & marketing in licensed regions, incl. the U.S.
- AVT03 is a fully human anti-RANKL mAb that will be available in single-dose pre-filled syringes (60mg/1mL) & single-dose vials (120mg/1.7mL or 70mg/mL) post approval
Ref: Alvotech | Image: Alvotech and Dr. Reddy’s| Press Release
Related News:- Alvotech and Teva Launch Selarsdi (Biosimilar, Stelara) in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
